Aciont
Envisioning the Future of Ocular Therapeutics
About Us | Unmet Needs | Technologies | Product Pipeline | Media & Investors

Welcome

Aciont® Inc. is a specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive, controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration. Aciont’s goal is to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye diseases through optimal drug dosing and improved patient/physician compliance.

One revolutionary aspect of our technology platform is the incorporation of a novel sustained release methodology for water soluble or poorly soluble drugs (commonly susceptible to ocular clearance effects) as part of a non-invasive or topical drug delivery system. Visulex’s passive diffusion-based sustained release system has demonstrated superior pharmacokinetic profiles over other technologies that deliver water soluble and poorly soluble agents passively and actively (iontophoresis) to the posterior pole of the eye and has been shown to treat retinal disease under a known preclinical model using a variety of proprietary pharmaceutical formulations and methods. Many of the leading back of the eye drug delivery technologies are invasive in nature because they target the eye’s interior regions such as the vitreous or retina, which often cannot be reached via conventional methods (e.g., eye drops).


Our Visulex® drug delivery system uses an easy to administer scleral lens shaped eye applicator worn for less than 10 minutes.
The timing is right for the next wave of Back of the Eye (BOTE) therapies as it will most likely require drug delivery differentiation, and Aciont is on the forefront of the wave.

Many of the leading BOTE drug delivery technologies are invasive in nature because they target the eye’s interior regions such as the vitreous or retina, which often cannot be reached via conventional methods (e.g., eye drops).

One revolutionary aspect of Aciont’s technology platform is the incorporation of a novel sustained release methodology in our Passive Delivery Applicator.

News

The NEI Awards $2.03 Million Commercialization SBIR Grant to Aciont · 05/09/2013 ·
Salt Lake City, UT – May 9, 2013. The National Eye Institute (NEI), a division o... [ more ] 
Aciont® to Present at ARVO 2013 Annual Meeting  · 04/15/2013 ·
Aciont Inc. announced today that Dr. Sarah A. Molokhia and Dr. Kongnara Papangk... [ more ] 
Aciont® To Present on VisulexTM Technologies at the 4th Ocular & Drug Discovery Conference · 01/10/2012 ·
Kongnara Papankorn and Sarah Molokhia will present on behalf of Aciont Inc at th... [ more ] 
Aciont® CEO to Present at IN3 West Medical Device Conference · 02/08/2011 ·
John Higuchi will present on behalf of Aciont Inc at the IN3 West Medical Device... [ more ] 
Aciont® Awarded Two Qualifying Therapeutic Discovery Project Grants Totaling $489K  · 11/04/2010 ·
Aciont Inc. announced today that it has been awarded $488,958 to support two pro... [ more ] 
The NIH Awards Aciont® a Small Business Catalyst Award Grant Accelerating Innovative Research · 07/07/2010 ·
Aciont is awarded a phase I SBIR $214K grant for the project titled "Novel Metho... [ more ] 
NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont® · 12/10/2009 ·
The National Eye Institute (NEI) awarded a $2.18 million grant to Aciont Inc. to... [ more ]